Adrenal Gland Neoplasms

Phase 4 trials (1)

• metyrapone

Phase 3 trials (10)

• 123i-iodometomidate
• doxorubicin
• i-131 iodocholesterol
• cisplatin
• etoposide
• mitotane
• sargramostim
• fludeoxyglucose f-18
• 11c-metomidate
• crn04894

Phase 2 trials (22)

• atezolizumab
• olaparib
• urea
• lapatinib
• amlodipine
• insulin human
• hydrocortisone
• nivolumab
• pembrolizumab
• osilodrostat
• ipilimumab
• pertuzumab
• temozolomide
• cabozantinib
• bms-986218
• erlotinib
• lutetium dotatate lu-177
• cemiplimab
• camrelizumab
• Tildacerfont
• nbi-74788
• ivocizumab

Phase 1 trials (11)

• fluoropaclitaxel
• atr-101
• deslorelin
• flutamide
• testolactone
• veliparib
• capecitabine
• tariquidar
• fapi-46
• [18f]ceto
• idov-immune

Other trials (10)

• diltiazem
• indapamide
• irbesartan
• prazosin
• spironolactone
• ramipril
• eplerenone
• amiloride
• bisoprolol
• sodium

Organization Involved with Phase 3 Indications (2)

• University of Michigan
• University of Texas at Houston

Organization Involved with Phase 2 Indications (1)

• Julius-Maximilians University

Organization Involved with Phase 1 Indications (3)

• Millendo Therapeutics, Inc.
• National Cancer Institute (NCI)
• University of California, Los Angeles

Organization Involved with Other Experimental Indications (1)

• University of Bordeaux